The association between impaired glucose tolerance and soluble CD40 ligand: a 15-year prospective cohort study

[1]  J. Malacara,et al.  Markers of the progression of complications in patients with type 2 diabetes: a one-year longitudinal study. , 2014, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[2]  E. Lutgens,et al.  CD40–CD40L: Linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications , 2013, Diabetes & vascular disease research.

[3]  E. Benjamin,et al.  Addition of Inflammatory Biomarkers Did Not Improve Diabetes Prediction in the Community: The Framingham Heart Study , 2012, Journal of the American Heart Association.

[4]  E. Benjamin,et al.  Metabolic syndrome and inflammatory biomarkers: a community-based cross-sectional study at the Framingham Heart Study , 2012, Diabetology & Metabolic Syndrome.

[5]  S. Grundy.  Pre-diabetes, metabolic syndrome, and cardiovascular risk. , 2012, Journal of the American College of Cardiology.

[6]  R. DeFronzo,et al.  Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. , 2011, The American journal of cardiology.

[7]  A. Newman,et al.  Inflammatory markers in population studies of aging , 2011, Ageing Research Reviews.

[8]  B. Pamukcu,et al.  The CD40-CD40L system in cardiovascular disease , 2011, Annals of medicine.

[9]  V. Basevi.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[10]  C. Leissinger,et al.  Prophylactic Dosing of Anti Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors Results of the Pro FEIBA Study , 2010 .

[11]  L. Boon,et al.  Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. , 2010, Blood.

[12]  D. Solmaz,et al.  Enhanced levels of soluble CD40 ligand and C-reactive protein in a total of 312 patients with metabolic syndrome. , 2010, Metabolism: clinical and experimental.

[13]  J. Börgel,et al.  Influence of glycaemic control on platelet bound CD40–CD40L system, P‐selectin and soluble CD40 ligand in Type 2 diabetes , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[14]  C. Stefanadis,et al.  The CD40/CD40 ligand system: linking inflammation with atherothrombosis. , 2009, Journal of the American College of Cardiology.

[15]  E. Benjamin,et al.  Clinical correlates, heritability, and genetic linkage of circulating CD40 ligand in the Framingham Offspring Study. , 2008, American heart journal.

[16]  G. Rossi,et al.  Diagnosis and Classification of Diabetes Mellitus The information that follows is based largely on the reports of the Expert Committee on the Diagnosis and Classification of Diabetes (Diabetes Care 20:1183–1197, 1997, and Diabetes Care 26:3160–3167, 2003). , 2008, Diabetes Care.

[17]  E. Coban,et al.  Platelet activation in subjects with impaired glucose tolerance , 2007, Platelets.

[18]  C. Ting,et al.  The presence of metabolic syndrome is independently associated with elevated serum CD40 ligand and disease severity in patients with symptomatic coronary artery disease. , 2006, Metabolism: clinical and experimental.

[19]  V. Mohan,et al.  Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome--the Chennai Urban Rural Epidemiology Study. , 2006, Metabolism: clinical and experimental.

[20]  P. Libby,et al.  Associations Between Soluble CD40 Ligand, Atherosclerosis Risk Factors, and Subclinical Atherosclerosis: Results from the Dallas Heart Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[21]  D. Newby,et al.  Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. , 2004, Atherosclerosis.

[22]  Henrik Vestergaard,et al.  The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. , 2004, Archives of internal medicine.

[23]  G. Lip,et al.  Soluble CD40 Ligand, Soluble P-Selectin, Interleukin-6, and Tissue Factor in Diabetes Mellitus: Relationships to Cardiovascular Disease and Risk Factor Intervention , 2004, Circulation.

[24]  Antonio Ceriello,et al.  Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemia. , 2004, American heart journal.

[25]  Jian Zhu,et al.  The effect of elevated serum soluble CD40 ligand on the prognostic value in patients with acute coronary syndromes. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[26]  P. Hjemdahl,et al.  Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with Type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation , 2004, Diabetologia.

[27]  Y. Jinchuan,et al.  Upregulation of CD40--CD40 ligand system in patients with diabetes mellitus. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[28]  Petr Jarolim,et al.  Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients: A Novel Target of Thiazolidinediones , 2003, Circulation.

[29]  G. Desideri,et al.  Effects of obesity and weight loss on soluble CD40L levels. , 2003, JAMA.

[30]  P. Libby,et al.  Soluble CD40L and Cardiovascular Risk in Women , 2001, Circulation.

[31]  E. Feskens,et al.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. , 2001, Archives of internal medicine.

[32]  S. Keinänen-Kiukaanniemi,et al.  Antihypertensive drugs as predictors of type 2 diabetes among subjects with impaired glucose tolerance. , 2000, Diabetes research and clinical practice.

[33]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[34]  Reinhold Förster,et al.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.

[35]  S. Keinänen-Kiukaanniemi,et al.  Prevalence of diabetes mellitus and impaired glucose tolerance in a middle-aged Finnish population. , 1995, Scandinavian journal of primary health care.